Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 41

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
,149 15,998 Depreciation of fixed assets and amortization of intangible assets48,490 37,289 Amortization of debt issuance costs1,694 1,444 Amortization of debt discount45 47 Gain on early extinguishment of debt— (7,518)Stock-based compensation30,025 25,675 Changes in contingent consideration(3,032)(2,297)Impairment of investment11,000 — Other net (gains) losses(5,887)109 Changes in operating assets and liabilities:  Accounts receivable, net(1,046)776 Inventories, net(22,871)915 Prepaid expenses and other assets(18,635)(1,309)Accounts payable9,344 2,772 Accrued expenses and income taxes payable(14,675)1,361 Other liabilities10,905 (790)Net cash provided by operating activities47,471 102,337 Investing activities:  Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)(16,702)— Purchases of fixed assets(11,245)(4,426)Purchases of available-for-sale investments(74,685)(105,781)Sales of available-for-sale investments140,416 79,462 Purchases of debt investments(1,250)— Net cash provided by (used in) investing activities36,534 (30,745)Financing activities:  Proceeds from shares issued under employee stock purchase plan1,569 1,364 Payment of employee withholding taxes on restricted stock unit vests(5,466)(382)Purchase of treasury stock, inclusive of broker fees(50,039)(25,000)Proceeds from 2029 convertible senior notes— 287,500 Repayment of 2024 convertible senior notes— (8,641)Repayment of 2025 convertible senior notes— (190,994)Repayment of Term loan A facility(6,563)(5,625)Purchase of capped call transactions— (26,709)Payment of debt issuance and financing costs— (9,350)Net cash (used in) provided by financing activities(60,499)22,163 Effect of exchange rate changes on cash and cash equivalents204 — Net increase in cash and cash equivalents23,710 93,755 Cash and